NEW YORK, Jan. 12, 2011 /PRNewswire/ -- InstaCare Corp. (OTC Bulletin Board: ISCR) a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that the company's Board of Directors has received the initial Guidance Report from Mr. William N. Walling, Jr., CFA. This report covers the 2011 guidance for the company's new Genstrip diagnostic product being sold exclusively through the company's Pharma Tech Solutions, Inc. subsidiary. The entire report is currently available for viewing on the company's website www.instacare.net.
Mr. Walling, an expert financial analyst specializing in the domestic healthcare paradigm, was contracted to review the company's performance, its progress with project development, product pipeline advancement, new product introduction (Genstrip) and financial results versus the stated plan. Mr. Walling's report includes an expectation of continued strength and market growth of current product offerings, and substantial industry traction with the company's new Genstrip diagnostic product with substantial revenue and margin contribution potential.
Keith Berman, Secretary and CFO of InstaCare Corp., commented: "Mr. Walling's report reinforces our internal confidence in the company's business model and strategic direction. This report concerning our new Genstrip diagnostic product should assure the investment community and company's shareholders that management and the BOD have faithfully executed the tasks documented in our plan enabling the attainment of all identified benchmarks. It should also confirm the validity of the company's business model and the viability of our continued success going forward into the future."
Mr. Walling will produce an additional report covering the company's core business which will be available in the coming weeks. The company also plans to schedule a shareholder conference call.
For more information about InstaCare Corp., Pharma Tech Solutions, Inc., the Genstrip and/or its revolutionary MD@Hand cell phone centric technologies, please visit the InstaCare web site www.instacare.net or call the company at (805) 446-2973.
Forward-Looking Statements:Forward-looking statements are statements made herein which do not address historical facts and, therefore could be interpreted to be forward-looking statements. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions. All forward-looking statements are intended to be covered by the safe harbor created by Section 21E of the Securities Exchange Act of 1934. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The forward-looking statements included in this press release represent our views as of January 11, 2011. We anticipate that subsequent events and developments will cause our views to change.Contact:Keith Berman, Secretary and CFOinfo@InstaCare.net
2660 Townsgate RoadSuite 300Westlake Village, CA 91361Ph : 805-446-2973Fax: 805-446-1983
|SOURCE InstaCare Corp.|
Copyright©2010 PR Newswire.
All rights reserved